Venclexta venetoclax: Phase Ib data

Data from 34 evaluable treatment-naive AML patients ages >65 in an open-label, dose-escalation, international Phase Ib trial showed that

Read the full 191 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE